Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
China-made extracorporeal membrane oxygenation products approved for US market launch
A disposable membrane oxygenator independently developed by a Chinese company received FDA approval in the United States on the 16th. Extracorporeal membrane oxygenation (ECMO) is a temporary life support device that replaces a patient’s heart and lung function, aiming to buy precious time for primary disease treatment and organ recovery in critically ill patients. It is also known as an “artificial heart-lung machine,” and the disposable membrane oxygenator is a core component of the ECMO system.
The disposable membrane oxygenator approved for sale in the U.S. was independently designed and developed by Shenzhen Hanno Medical Technology Co., Ltd. The company’s ECMO system was approved for market launch in China in 2023, breaking the monopoly of European and American products in the Chinese market. In 2025, the ECMO system received certification from the South German Certification and Testing Company recognized by the European Union.
According to Shenzhen Hanno Medical Technology Co., Ltd., its ECMO system has achieved full control over the entire supply chain from materials to the complete machine. It has now gained market access in more than 40 countries and regions worldwide. (Xinhua News Agency)